Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04803955Phase 2Recruiting

Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients

Role: lead

NCT04343859Phase 1Unknown

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors

Role: lead

NCT03237728Phase 1Completed

Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients

Role: lead

NCT02690961Phase 1Completed

Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

Role: lead

NCT02219971Phase 1Completed

Phase I Study of Kukoamine B Mesilate in Healthy Volunteers

Role: lead

All 5 trials loaded